SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies

被引:1
|
作者
Badano, Maria Noel [1 ,2 ]
Pereson, Matias J. [3 ]
Sabbione, Florencia [1 ]
Keitelman, Irene [1 ]
Aloisi, Natalia [2 ]
Chuit, Roberto [4 ]
de Bracco, Maria M. E. [1 ]
Fink, Susana [1 ]
Bare, Patricia [1 ,2 ]
机构
[1] Acad Nacl Med Buenos Aires, Consejo Nacl Invest Cient & Tecn CONICET, Inst Med Expt IMEX, RA-1425 Buenos Aires, DF, Argentina
[2] Acad Nacl Med Buenos Aires, Inst Invest Hematol IIHEMA, RA-1425 Buenos Aires, DF, Argentina
[3] Univ Buenos Aires, Fac Farm & Bioquim, Inst Invest Bacteriol & Virol Mol IBaViM, RA-1113 Buenos Aires, DF, Argentina
[4] Acad Nacl Med Buenos Aires, IIE, RA-1425 Buenos Aires, DF, Argentina
关键词
SARS-CoV-2 breakthrough infections; vaccines; anti-spike antibody levels; humoral response; IgG specific salivary antibodies; SERUM;
D O I
10.3390/vaccines11030534
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
SARS-CoV-2 breakthrough infections, associated with waning immunity, increase systemic antibody levels. In this study, we analyzed the impact of the infection timing on the magnitude of the systemic humoral response and whether breakthrough infections also boost antibody levels in the salivary compartment. We observed that the combination of infection plus vaccination, regardless of infection timing, produced a sharp increase in systemic antibodies, which were higher in subjects infected after third doses. Moreover, despite high systemic antibody levels, breakthrough infections after dose three occurred and boosted antibody levels in the salivary compartment. These results suggest that current vaccination strategies against COVID-19 should be improved. Results also showed that determination of salivary antibodies against SARS-CoV-2 could be a valuable tool in disease prevalence studies, for the follow-up of vaccinated individuals, and to assist vaccination strategies against COVID-19, especially in settings where blood sampling cannot be fulfilled.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
    Tober-Lau, Pinkus
    Gruell, Henning
    Vanshylla, Kanika
    Koch, Willi M.
    Hillus, David
    Schommers, Philipp
    Suarez, Isabelle
    Suttorp, Norbert
    Sander, Leif Erik
    Klein, Florian
    Kurth, Florian
    EMERGING INFECTIOUS DISEASES, 2022, 28 (05) : 1050 - 1052
  • [42] Role of anti-Spike SARS-CoV-2 IgG antibodies in protection from SARS-CoV-2 Infection after booster vaccination
    Senn, A.
    Brueckner-Fracowiak, J.
    Kostyra, J.
    Biedermann, S.
    Fux, A.
    Bach, A.
    Schuster, M.
    Baurmann, H.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 : 363 - 363
  • [43] Long COVID after breakthrough SARS-CoV-2 infection
    Al-Aly, Ziyad
    Bowe, Benjamin
    Xie, Yan
    NATURE REVIEWS IMMUNOLOGY, 2022, 22 (07) : 410 - 410
  • [44] Long COVID after breakthrough SARS-CoV-2 infection
    Ziyad Al-Aly
    Benjamin Bowe
    Yan Xie
    Nature Medicine, 2022, 28 (7) : 1461 - 1467
  • [45] Long COVID after breakthrough SARS-CoV-2 infection
    Al-Aly, Ziyad
    Bowe, Benjamin
    Xie, Yan
    NATURE MEDICINE, 2022, 28 (07) : 1461 - +
  • [46] Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination
    Walmsley, Sharon
    Nabipoor, Majid
    Lovblom, Leif Erik
    Ravindran, Rizani
    Colwill, Karen
    Mcgeer, Alison
    Dayam, Roya Monica
    Manase, Dorin
    Gingras, Anne-Claude
    VACCINES, 2024, 12 (01)
  • [47] Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies
    Tre-Hardy, Marie
    Wilmet, Alain
    Beukinga, Ingrid
    Favresse, Julien
    Dogne, Jean-Michel
    Douxfils, Jonathan
    Blairon, Laurent
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (02) : 803 - 811
  • [48] Seroprevalence of SARS-CoV-2 specific IgG antibodies in rural population of Western Maharashtra, India
    Agarwal, Dhiraj
    Patil, Rutuja
    Roy, Sudipto
    Kaur, Harshpreet
    Mehandale, Sanjay
    Bavdekar, Ashish
    Nair, Harish
    Juvekar, Sanjay
    Dayma, Girish
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [49] Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
    Abu-Raddad, Laith J.
    Chemaitelly, Hiam
    Ayoub, Houssein H.
    Tang, Patrick
    Coyle, Peter
    Hasan, Mohammad R.
    Yassine, Hadi M.
    Benslimane, Fatiha M.
    Al-Khatib, Hebah A.
    Al-Kanaani, Zaina
    Al-Kuwari, Einas
    Jeremijenko, Andrew
    Kaleeckal, Anvar Hassan
    Latif, Ali Nizar
    Shaik, Riyazuddin Mohammad
    Abdul-Rahim, Hanan F.
    Nasrallah, Gheyath K.
    Al-Kuwari, Mohamed Ghaith
    Butt, Adeel A.
    Al-Romaihi, Hamad Eid
    Al-Khal, Abdullatif
    Al-Thani, Mohametabd H.
    Bertollini, Roberto
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [50] Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
    Laith J. Abu-Raddad
    Hiam Chemaitelly
    Houssein H. Ayoub
    Patrick Tang
    Peter Coyle
    Mohammad R. Hasan
    Hadi M. Yassine
    Fatiha M. Benslimane
    Hebah A. Al-Khatib
    Zaina Al-Kanaani
    Einas Al-Kuwari
    Andrew Jeremijenko
    Anvar Hassan Kaleeckal
    Ali Nizar Latif
    Riyazuddin Mohammad Shaik
    Hanan F. Abdul-Rahim
    Gheyath K. Nasrallah
    Mohamed Ghaith Al-Kuwari
    Adeel A. Butt
    Hamad Eid Al-Romaihi
    Abdullatif Al-Khal
    Mohametabd H. Al-Thani
    Roberto Bertollini
    Nature Communications, 13